HepaCute is composed of 17 partnering organizations from 5 member states (Germany, France, Spain, Italy, United-Kingdom), 1 associated country (Switzerland) and 2 International Cooperation Partner Countries (Egypt and Morocco).

Objectives

A combined strategy of increased acute hepatitis C detection and efficient patient management could dramatically decrease the number of new cases of chronic hepatitis C and reduce treatment-related morbidity

In this context, the HepaCute project’s major objectives are:

1. To increase acute hepatitis C detection rate(s) in European and Egyptian model regions
2. To understand host genetic factors and their functional impact on innate and adaptive antiviral immune responses that control acute HCV infection
3. To understand the role of viral fitness and evolution in relation to adaptive humoral and cellular immunity
4. To identify biomarkers of spontaneous acute hepatitis C resolution
5. To improve clinical care of patients with acute hepatitis C in Europe and Mediterranean Partner Countries (MPC)
6. To establish synergistic collaboration between European (EU-funded HepaCute and SPHINX projects) and Egyptian STDF funded (the Science and Technology Development Fund) research programmes on HCV and HCV patient management and to build research capacity.